Literature DB >> 10672454

Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?

S Vijan1, D M Kent, R A Hayward.   

Abstract

Randomized controlled trials (RCTs) are often considered the standard for defining the practice of evidence-based medicine. Taken alone, they are, however, often insufficient to guide clinical care. Randomized controlled trials are clearly the best method to determine whether interventions are efficacious. They have, however, numerous limitations which make them difficult to carry out or limit applicability to routine clinical practice. Although observational studies also have inherent limitations, they provide data which can help to further explain the results of randomized controlled trials. The use of observational studies to frame randomized trials can allow better application of randomized controlled trial results to individual patients and can thus help to optimize delivery of care, inform clinical practice and determine the need for further such trials.

Entities:  

Mesh:

Year:  2000        PMID: 10672454     DOI: 10.1007/s001250050017

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Controlling glucose and blood pressure in type 2 diabetes.

Authors:  J Tuomilehto
Journal:  BMJ       Date:  2000-08-12

2.  Prevalence of diabetes treatment effect modifiers: the external validity of trials to older adults.

Authors:  Carlos O Weiss; Cynthia M Boyd; Jennifer L Wolff; Bruce Leff
Journal:  Aging Clin Exp Res       Date:  2012-08       Impact factor: 3.636

3.  Racial and Ethnic Approaches to Community Health (REACH) Detroit partnership: improving diabetes-related outcomes among African American and Latino adults.

Authors:  Jacqueline Two Feathers; Edith C Kieffer; Gloria Palmisano; Mike Anderson; Brandy Sinco; Nancy Janz; Michele Heisler; Mike Spencer; Ricardo Guzman; Janice Thompson; Kimberlydawn Wisdom; Sherman A James
Journal:  Am J Public Health       Date:  2005-07-28       Impact factor: 9.308

4.  Geographic Information Systems to Assess External Validity in Randomized Trials.

Authors:  Margaret R Savoca; David A Ludwig; Stedman T Jones; K Jason Clodfelter; Joseph B Sloop; Linda Y Bollhalter; Alain G Bertoni
Journal:  Am J Prev Med       Date:  2017-02-23       Impact factor: 5.043

5.  Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus.

Authors:  Yi-Jen Hung; Shi-Wen Kuo; Chao-Hung Wang; Hung-Yu Chang; Sheng-Hwu Hsieh; Harald Landen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

6.  Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantation.

Authors:  M Wagner; E M Balk; D M Kent; B L Kasiske; H Ekberg
Journal:  Am J Transplant       Date:  2009-10       Impact factor: 8.086

7.  Effect of add-on acarbose to insulin therapy in routine clinical practice.

Authors:  K R Klocke; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

8.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

Authors:  David M Kent; Peter M Rothwell; John P A Ioannidis; Doug G Altman; Rodney A Hayward
Journal:  Trials       Date:  2010-08-12       Impact factor: 2.279

9.  Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Authors:  Rodney A Hayward; David M Kent; Sandeep Vijan; Timothy P Hofer
Journal:  BMC Med Res Methodol       Date:  2006-04-13       Impact factor: 4.615

10.  Myocardial infarction risk and tamoxifen therapy for breast cancer.

Authors:  A M Geiger; W Chen; L Bernstein
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.